USPTO serial 79296383
SAGA DIAGNOSTICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 5, 2021
- Examiner
- CARROLL, DORITT
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with SAGA DIAGNOSTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biopharmaceuticals for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; biological preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; chemical preparations for use in DNA analysis for medical purposes; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the prevention of tumours; tumor suppressing agents; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for treating malignant tumors; nucleic acid sequences for medical and veterinary purposes; medical diagnostic reagents and assays for testing of body fluids; clinical medical reagents; veterinary diagnostic reagents; medical diagnostic reagents; reagents for medical use; chemical reagents for veterinary use; chemical reagents for medical use; reagents for microbiological analysis for veterinary use; reagents for microbiological analysis for medical use; diagnostic reagents for medical use; diagnostic reagents for medicinal use; immunoassay reagents for medical use; diagnostic biomarker reagents for medical purposes; diagnostic chemical reagents for medical use; chemical diagnostic reagents for medical use; reagents for analytical purposes for medical purposes; reagents for blood grouping for medical purposes; reagents for microbiological analysis for medical purposes; reagents for analytical purposes for veterinary purposes; reagents for microbiological analysis for veterinary purposes; reagents for use in diagnostic pregnancy tests; chemical reagents for medical or veterinary purposes; reagents for use in analysis for veterinary purposes; reagents for use in analysis for medical purposes; reagents for use with analyzers for medical purposes; reagents for use with analyzers for veterinary purposes; reagents for use in diagnostic tests for medical purposes; reagents for use in diagnostic tests for veterinary purposes; reagents for in-vitro laboratory use for medical purposes; reagents and media for medical and veterinary diagnostic purposes; reagents for in-vitro laboratory use for veterinary purposes; genetic identity tests comprised of reagents for medical purposes; medical diagnostic reagents and assays for testing of body fluids; reagents for use in veterinary genetic testing; genetic identity tests comprised of reagents for medical purposes | ACTIVE | — |
| 042 | Scientific research for medical purposes in the area of cancerous diseases; scientific laboratory services, laboratory research services relating to detection of sequence variants in DNA or RNA; laboratory testing services relating to detection of sequence variants in DNA or RNA; analytical medical laboratory services; analytical veterinary laboratory services; scientific laboratory services; medical laboratory services; veterinary laboratory services; medical chemical laboratory services; medical biological laboratory services; medical research laboratory services; medical chemical research laboratory services; medical biological research laboratory services; medical laboratory services for analytical testing; medical services of a chemical laboratory; DNA testing services to determine paternity laboratory services; laboratory research services relating to dermatology; laboratory research services relating to pharmaceuticals; medical services of a chemical and/or biological laboratory; medical laboratory services relating to the production of monoclonal antibodies; DNA screening for scientific research purposes; clinical trials for others; conducting clinical trials for others; conducting clinical trials for pharmaceutical products for others; conducting clinical trials in the field of cardiovascular disease for others; conducting clinical trials in the field of acupuncture therapy for others; providing information about the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; clinical research in the field of cancer and infectious diseases; biological research, clinical research and medical research; basic and clinical research in the field of respiratory science and medicine; pharmaceutical research services; research on the subject of pharmaceuticals; pharmaceutical research and development; research relating to pharmaceuticals; pharmaceutical research and development services; laboratory research services relating to pharmaceuticals; research on the subject of pharmaceuticals; consultancy relating to pharmaceutical research and development; research and development for the pharmaceutical industry; consultancy in the field of pharmaceutical research; research and development in the pharmaceutical and biotechnology fields; scientific research, namely, genetic engineering services; scientific research in the field of genetics and genetic engineering; scientific research relating to genetics; genetic testing for scientific research purposes; scientific research, namely, genetic engineering services relating to plants; medical research in the field of gene therapy; scientific research relating to genetics of plants; laboratory research in the field of gene expression; genetic testing of laboratory animals for research purposes | ACTIVE | — |
| 044 | Lung cancer screening services; prostate cancer screening services; breast cancer screening services; bowel cancer screening services; cervical cancer screening services; providing cancer screening services; testicular cancer screening services; medical analysis services for the diagnosis of cancer; medical analysis services for cancer diagnosis and prognosis; medical services for the treatment of skin cancer; RNA or DNA analysis for cancer diagnosis and prognosis provided by medical laboratories; genetic testing of animals for diagnostic or treatment purposes; medical testing for diagnostic or treatment purposes; DNA screening for medical purposes; drug, alcohol and DNA screening for medical purposes; RNA or DNA analysis for cancer diagnosis and prognosis; medical and health services relating to DNA, genetics and genetic testing; genetic counseling; genetic testing of animals for diagnostic or treatment purposes; genetic testing for medical purposes; genetic testing of animals for diagnostic or treatment purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SAGA Diagnostics AB
- Other trademarks owned by SAGA Diagnostics AB
- Other trademarks owned by SAGA Diagnostics AB
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named SAGA DIAGNOSTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 24, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 15, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 15, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 15, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Dec 15, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 15, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 15, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 18, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 24, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 24, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jan 21, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 5, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 5, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 20, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 20, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 19, 2021 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jun 30, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 30, 2021 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jun 30, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 14, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 14, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 14, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 14, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 14, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 1, 2021 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jun 1, 2021 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 1, 2021 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 1, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 30, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 30, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 4, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 11, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 11, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 26, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 25, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 24, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 19, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Nov 19, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Nov 19, 2020 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Nov 19, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 19, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Nov 19, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 18, 2020 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Nov 18, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 18, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 13, 2020 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 22, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |